Oleoylethanolamide

Last Updated: September 28 2022

Oleoylethanolamide (OEA) is a molecule produced in the body, usually found in the intestines. It is responsible for the feeling of satiety after meals. Further research is needed to determine if oral supplementation of OEA provides benefits for weight loss.

Oleoylethanolamide is most often used for

Summary

Oleoylethanolamide (OEA) is a molecule produced in the body, usually found in the intestines. It is responsible for the feeling of satiety following meals.

OEA is sometimes included in fat burning supplement stacks. There is currently no human evidence that suggests oral supplementation of OEA is able to burn fat.

OEA acts on a receptor called Peroxisome Proliferator-Activated Receptor Alpha (PPARα). When this receptor is activated in the intestines of rats, the animals consume less food. Research on rats shows that both injections and oral intake of OEA causes a reliable reduction in the amount of food eaten.

Limited human evidence suggests that OEA may be able to aid fat loss by acting on PPARα. When this receptor is activated in fat tissue, energy expenditure increases. Further evidence is needed before oral supplementation of OEA can be recommended for weight loss.

What else is Oleoylethanolamide known as?
Note that Oleoylethanolamide is also known as:
  • OEA
  • NOPE (a precursor)
Dosage information

Research on rats has observed effects at a daily dose of 10mg/kg of bodyweight. This is roughly equivalent to the following human dosages:

  • 128.5 mg for a 150 lb person
  • 171.4 mg for a 200 lb person
  • 214.3 mg for a 250 lb person

Join our supplement information course

Don't miss out on the latest research

References
1.^Serrano A, Pavón FJ, Tovar S, Casanueva F, Señarís R, Diéguez C, de Fonseca FROleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating food intakeNeuropharmacology.(2011 Mar)
2.^Petrosino S, Di Marzo VAnandamide and Other AcylethanolamidesHandbook of Neurochemistry and Molecular Neurobiology.(2010)
3.^Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli DOleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alphaNature.(2003 Sep 4)
4.^Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F, Destaillats FBiological functions and metabolism of oleoylethanolamideLipids.(2008 Oct)
6.^Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli DFormation and inactivation of endogenous cannabinoid anandamide in central neuronsNature.(1994 Dec 15)
7.^Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NBMolecular characterization of an enzyme that degrades neuromodulatory fatty-acid amidesNature.(1996 Nov 7)
8.^Gaetani S, Oveisi F, Piomelli DModulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamideNeuropsychopharmacology.(2003 Jul)
10.^Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet CDeorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agentsCell Metab.(2006 Mar)
11.^Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJThe orphan receptor GPR55 is a novel cannabinoid receptorBr J Pharmacol.(2007 Dec)
12.^Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos GEvidence for novel cannabinoid receptorsPharmacol Ther.(2005 May)
13.^Petitet F, Donlan M, Michel AGPR55 as a new cannabinoid receptor: still a long way to prove itChem Biol Drug Des.(2006 Mar)
15.^Nielsen MJ, Petersen G, Astrup A, Hansen HSFood intake is inhibited by oral oleoylethanolamideJ Lip Res.(2004 Apr 1)
16.^Schmid PC, Zuzarte-Augustin ML, Schmid HHProperties of rat liver N-acylethanolamine amidohydrolaseJ Biol Chem.(1985 Nov 15)
17.^Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, Kato IDistribution of anandamide amidohydrolase in rat tissues with special reference to small intestineBiochim Biophys Acta.(1997 Aug 16)
18.^Cox JE, Tyler WJ, Randich A, Kelm GR, Bharaj SS, Jandacek RJ, Meller STSuppression of food intake, body weight, and body fat by jejunal fatty acid infusionsAm J Physiol Regul Integr Comp Physiol.(2000 Mar)
19.^Murillo-Rodríguez E, Palomero-Rivero M, Millán-Aldaco D, Arias-Carrión O, Drucker-Colín RAdministration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in ratsPLoS One.(2011)
20.^Arletti R1, Benelli A, Bertolini AInfluence of oxytocin on feeding behavior in the ratPeptides.(1989 Jan-Feb)
21.^Deblon N1, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier AL, Petrosino S, Piscitelli F, Legros JJ, Geenen V, Foti M, Wahli W, Di Marzo V, Rohner-Jeanrenaud FMechanisms of the anti-obesity effects of oxytocin in diet-induced obese ratsPLoS One.(2011)
22.^Zhang G1, Bai H, Zhang H, Dean C, Wu Q, Li J, Guariglia S, Meng Q, Cai DNeuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balanceNeuron.(2011 Feb 10)
23.^Gimpl G1, Fahrenholz FThe oxytocin receptor system: structure, function, and regulationPhysiol Rev.(2001 Apr)
24.^Gaetani S, Fu J, Cassano T, Dipasquale P, Romano A, Righetti L, Cianci S, Laconca L, Giannini E, Scaccianoce S, Mairesse J, Cuomo V, Piomelli DThe fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocinJ Neurosci.(2010 Jun 16)
26.^Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne BRat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeedingEndocrinology.(2001 Oct)
27.^Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli DAn anorexic lipid mediator regulated by feedingNature.(2001 Nov 8)
28.^Little TJ, Horowitz M, Feinle-Bisset CRole of cholecystokinin in appetite control and body weight regulationObes Rev.(2005 Nov)
29.^Batterham RL, Bloom SRThe gut hormone peptide YY regulates appetiteAnn N Y Acad Sci.(2003 Jun)
30.^Jin P, Yu HL, Tian-Lan, Zhang F, Quan ZSAntidepressant-like effects of oleoylethanolamide in a mouse model of chronic unpredictable mild stressPharmacol Biochem Behav.(2015 Jun)
31.^Suárez J, Rivera P, Arrabal S, Crespillo A, Serrano A, Baixeras E, Pavón FJ, Cifuentes M, Nogueiras R, Ballesteros J, Dieguez C, Rodríguez de Fonseca FOleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in ratDis Model Mech.(2014 Jan-Feb)
32.^Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BBbetaAR signaling required for diet-induced thermogenesis and obesity resistanceScience.(2002 Aug 2)
33.^White CL, Ishihara Y, Dotson TL, Hughes DA, Bray GA, York DAEffect of a beta-3 agonist on food intake in two strains of rats that differ in susceptibility to obesityPhysiol Behav.(2004 Sep 15)
35.^Klein J, Fasshauer M, Benito M, Kahn CRInsulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expressionMol Endocrinol.(2000 Jun)
37.^Villarroya F, Iglesias R, Giralt MPPARs in the Control of Uncoupling Proteins Gene ExpressionPPAR Res.(2007)
41.^Lan H, Lin HV, Wang CF, Wright MJ, Xu S, Kang L, Juhl K, Hedrick JA, Kowalski TJAgonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathwaysBr J Pharmacol.(2012 Apr)
43.^Stone VM, Dhayal S, Smith DM, Lenaghan C, Brocklehurst KJ, Morgan NGThe cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119Br J Pharmacol.(2012 Apr)
44.^Galan-Rodriguez B, Suarez J, Gonzalez-Aparicio R, Bermudez-Silva FJ, Maldonado R, Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo EOleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neuronsNeuropharmacology.(2009 Mar)
46.^Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet RPeroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatmentJ Neurosci.(2003 Jul 16)
47.^Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi ADistribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and humanProc Natl Acad Sci U S A.(2000 Mar 28)